deltatrials
Unknown PHASE2 INTERVENTIONAL 1-arm NCT03497702

Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer (NeoChAI)

Phase II Study of Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer

Sponsor: National Cancer Center, Korea

Conditions Breast Cancer Invasive Breast Cancer
Interventions Cyclophosphamide Docetaxel Doxorubicin Letrozole leuprorelin
Updated 7 times since 2018 Last updated: Apr 12, 2018 Started: May 8, 2017 Primary completion: Nov 30, 2023 Completion: Jan 31, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03497702, this PHASE2 trial focuses on Breast Cancer and Invasive Breast Cancer and remains ongoing. Sponsored by National Cancer Center, Korea, it has been updated 7 times since 2017, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~May 2018 – ~Jun 2018 · 31 days · monthly snapshotRecruiting~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotRecruiting~Jan 2021 – ~Feb 2024 · 37 months · monthly snapshotRecruiting~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotUnknown~Sep 2025 – present · 10 months · monthly snapshotUnknown

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  4. Feb 2024 — Jul 2024 [monthly]

    Unknown Status PHASE2

    Status: Recruiting → Unknown Status

  5. Jan 2021 — Feb 2024 [monthly]

    Recruiting PHASE2

▶ Show 2 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Recruiting PHASE2

  2. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

    First recorded

May 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Center, Korea
Data source: National Cancer Center, Korea

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations